凱普生物(300639.SZ)擬於創業板非公開發行股份募資不超10.50億元
格隆匯2月13日丨凱普生物(300639.SZ)發佈2020年度創業板非公開發行A股股票預案,本次非公開發行數量按照募集資金總額除以發行價格確定,且不超過本次發行前總股本的20%,即不超過4249.0856萬股(含本數)。
本次非公開發行股票的發行對象為包括公司實際控制人之一、董事及高級管理人員管秩生在內的不超過5名特定對象。
本次非公開發行募集資金總額不超過10.50億元(含發行費用),公司擬將扣除發行費用後的募集資金用於核酸分子診斷產品產業化項目,第三方醫學實驗室升級項目,核酸分子診斷產品研發項目,抗HPV藥物研發項目及補充運營資金。
本次公司非公開發行將增加公司核酸分子診斷試劑生產車間面積,擴大核酸分子診斷試劑產能,進一步提升各系列HPV檢測試劑盒及STD十聯檢產品的生產能力,不斷滿足市場對HPV、STD的檢測需求,提升公司在該領域的市場滲透度,鞏固公司自身的行業地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.